Henning Nilius

University of Bern

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (7)

Michael Daskalakis

Assistant Professor, Head of Cellular Therapy Division, Director of autologous Stem Cell Program Inselspital

Inselspital Universitätsspital Bern

SWITZERLAND

View details

Michael Nagler

SWITZERLAND

View details

Carlo Largiader

University Hospital of Bern

SWITZERLAND

View details

Katja Seipel

University Hospital of Bern

SWITZERLAND

View details

Prakash Vishnu

Associate Professor

University of Washington

UNITED STATES

View details

Thomas Pabst

SWITZERLAND

View details

Philipp Jent

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Henning Nilius

Research Interests

Explore related searches

Contact this professor

Articles (20)

Clinical Impact of CTLA-4 Single-Nucleotide Polymorphism in DLBCL Patients Treated with CAR-T Cell Therapy

Impact of Venetoclax Treatment Schedule on Hematologic Recovery and Treatment Response in AML Patients Unfit for Intensive Chemotherapy

Assessing the Reliability of D-Dimer Measurement in EDTA Plasma: A Comparison to the Established Citrate Method

Prevalence of functional iron deficiency in patients with malignancies and its impact on fatigue-specific quality of life

Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

Estimating the prevalence of adults at risk for advanced hepatic fibrosis using FIB-4 in a Swiss tertiary care hospital

Rising Prevalence of Low-Frequency <i>PPM1D</i> Gene Mutations after Second HDCT in Multiple Myeloma

Safety and Efficacy of High-Dose Chemotherapy with TreoMel 200 vs. TreoMel 140 in Acute Myeloid Leukemia Patients Undergoing Autologous Stem Cell Transplantation

Gender-Specific Prognostic Impact of Treosulfan Levels in High-Dose Chemotherapy for Multiple Myeloma

Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy

Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome

Determination of the Diagnostic Performance of Laboratory Tests in the Absence of a Perfect Reference Standard: The Case of SARS-CoV-2 Tests

Next‐generation diagnostic instruments in haematology

A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: a prospective, multicenter, observational study

Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma

Current Knowledge on Factor V Leiden Mutation as a Risk Factor for Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis

Current Knowledge on Factor V Leiden Mutation as a Risk Factor for Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis

Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients

Long‐term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients

Secondary prevention of venous thromboembolism: Predictors and outcomes of guideline adherence in a long-term prospective cohort study

Collaborators (7)

Michael Daskalakis

Michael Nagler

Carlo Largiader

Katja Seipel

Prakash Vishnu

Thomas Pabst

Philipp Jent

Make your next move.